Advertisement
Canada markets close in 5 hours 10 minutes

  • S&P/TSX

    21,742.26
    -131.46 (-0.60%)
     

  • S&P 500

    5,002.04
    -69.59 (-1.37%)
     

  • DOW

    37,778.43
    -682.49 (-1.77%)
     

  • CAD/USD

    0.7297
    -0.0000 (-0.01%)
     

  • CRUDE OIL

    82.33
    -0.48 (-0.58%)
     

  • Bitcoin CAD

    86,894.70
    -2,289.27 (-2.57%)
     

  • CMC Crypto 200

    1,377.11
    -5.46 (-0.40%)
     

  • GOLD FUTURES

    2,355.50
    +17.10 (+0.73%)
     

  • RUSSELL 2000

    1,967.51
    -27.92 (-1.40%)
     

  • 10-Yr Bond

    4.7160
    +0.0640 (+1.38%)
     

  • NASDAQ

    15,437.01
    -275.74 (-1.75%)
     

  • VOLATILITY

    16.96
    +0.99 (+6.20%)
     

  • FTSE

    8,063.46
    +23.08 (+0.29%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6807
    -0.0012 (-0.18%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

Stocks in play: Oncolytics Biotech Inc

Baystreet.ca
·1 min read

Announced that the pancreatic cancer cohort of the multi-indication phase 1/2 GOBLET study has met the efficacy expansion criteria for Stage 1 of the trial. The data from the phase 1b portion of this cohort are featured in an abstract accepted for a poster presentation at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2022, and show a strong efficacy signal as evidenced by all patients achieving a partial response. The trial's metastatic colorectal and advanced anal cancer cohorts are proceeding as planned. Oncolytics Biotech Inc shares T.ONC are trading up $0.06 at $1.36.

Read: